Combination chemotherapy with topotecan for non-small cell lung cancerDOWLATI, Afshin; LEVITAN, Nathan.Lung cancer. 2003, Vol 41, pp S23-S26, issn 0169-5002, SUP4Article

Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free SurvivalPINGFU FU; DOWLATI, Afshin; SCHLUCHTER, Mark et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4135-4141, issn 0732-183X, 7 p.Article

Five-year survival does not equal cure in non-small cell lung cancer: A Surveillance, Epidemiology, and End Results―based analysis of variables affecting 10- to 18-year survivalHUBBARD, Matthew O; PINGFU FU; MARGEVICIUS, Seunghee et al.Journal of thoracic and cardiovascular surgery (Print). 2012, Vol 143, Num 6, pp 1307-1313, issn 0022-5223, 7 p.Article

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung CancerTreated with Chemotherapy with or without Bevacizumab : an Eastern Cooperative Oncology Group StudyDOWLATI, Afshin; GRAY, Robert; SANDLER, Alan B et al.Clinical cancer research. 2008, Vol 14, Num 5, pp 1407-1412, issn 1078-0432, 6 p.Article

Multi-Institutional Phase I Trials of Anticancer AgentsDOWLATI, Afshin; MANDA, Sudhir; GIBBONS, Joseph et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1926-1931, issn 0732-183X, 6 p.Article

Activation state egfr and STAT-3 as prognostic markers in resected non-small cell lung cancerCORTAS, Tania; EISENBERG, Rosana; FU, Pingfu et al.Lung cancer. 2007, Vol 55, Num 3, pp 349-355, issn 0169-5002, 7 p.Article

Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer : the use of complete response rate as the primary endpoint in phase II trialsDOWLATI, Afshin; CROSBY, Lori; REMICK, Scot C et al.Lung cancer. 2001, Vol 32, Num 2, pp 155-162, issn 0169-5002Article

Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancerKLUGE, Amy; DABIR, Snehal; KERN, Jeffrey et al.International journal of cancer (Print). 2009, Vol 125, Num 7, pp 1728-1734, issn 0020-7136, 7 p.Article

A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancerHALMOS, Balazs; YUXIA JIA; BOKAR, Joseph A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1244-1250, issn 0167-6997, 7 p.Article

Quantifying EGFR Alterations in the Lung Cancer Genome with Nanofluidic Digital PCR ArraysJUN WANG; RAMAKRISHNAN, Ramesh; ZHE TANG et al.Clinical chemistry (Baltimore, Md.). 2010, Vol 56, Num 4, pp 623-632, issn 0009-9147, 10 p.Article

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 statusDABIR, Snehal; KLUGE, Amy; MCCOLL, Karen et al.International journal of cancer (Print). 2014, Vol 134, Num 5, pp 1045-1054, issn 0020-7136, 10 p.Article

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancerSHARMA, Neelesh; PENNELL, Nathan; NICKOLICH, Myles et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 362-368, issn 0167-6997, 7 p.Article

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical CancerKUNOS, Charles A; WAGGONER, Steven; VON GRUENIGEN, Vivian et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1298-1306, issn 1078-0432, 9 p.Article

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2LILENBAUM, Rogerio; AXELROD, Rita; THOMAS, Sachdev et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 863-869, issn 0732-183X, 7 p.Article

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerSANDIER, Alan; GRAY, Robert; PERRY, Michael C et al.The New England journal of medicine. 2006, Vol 355, Num 24, pp 2542-2550, issn 0028-4793, 9 p.Article

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR PathwayBUSAIDY, Naifa L; FAROOKI, Azeez; DOWLATI, Afshin et al.Journal of clinical oncology. 2012, Vol 30, Num 23, pp 2919-2928, issn 0732-183X, 10 p.Article

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaBRELL, Joanna M; KRISHNAMURTHI, Smitha S; IVY, S. Percy et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 851-857, issn 0344-5704, 7 p.Article

Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment StrategiesZHIWEI YU; BOGGON, Titus J; KOBAYASHI, Susumu et al.Cancer research (Baltimore). 2007, Vol 67, Num 21, pp 10417-10427, issn 0008-5472, 11 p.Article

A Phase 1 /Pharmacokinetic Study of Sunitinib in Combination With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Positive Patients With Cancer: AIDS Malignancy Consortium Trial AMC 061RUDEK, Michelle A; MOORE, Page C; HAIGENTZ, Missak et al.Cancer. 2014, Vol 120, Num 8, pp 1194-1202, issn 0008-543X, 9 p.Article

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabineKRISHNAMURTHI, Smitha S; BRELL, Joanna M; COONEY, Matthew M et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 3, pp 441-450, issn 0344-5704, 10 p.Article

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignanciesSPECTOR, Neil L; WENLE XIA; SMITH, Deborah A et al.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2502-2512, issn 0732-183X, 11 p.Conference Paper

Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose Phase I study in patients with advanced cancerCOONEY, Matthew M; RADIVOYEVITCH, Tomas; STAMBLER, Bruce S et al.Clinical cancer research. 2004, Vol 10, Num 1, pp 96-100, issn 1078-0432, 5 p., 1Article

Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive daysDOWLATI, Afshin; HOPPEL, Charles L; INGALLS, Stephen T et al.Journal of clinical oncology. 2001, Vol 19, Num 8, pp 2309-2318, issn 0732-183XArticle

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancerDOWLATI, Afshin; LEVITAN, Nathan; GORDON, Nahida H et al.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 2, pp 141-148, issn 0344-5704Article

Phase I trial of pomalidomide given for patients with advanced solid tumorsCOONEY, Matthew M; NOCK, Charles; BOKAR, Joseph et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 5, pp 755-761, issn 0344-5704, 7 p.Article